14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Wed, 26 Jun 2024

Trading levels for NVAX

Fibonacci Support & Resistance Levels

Level Price
R3 14.39 2.81%
R2 14.22 1.58%
R1 14.12 0.82%
Price 14.00
S1 13.77 -1.63%
S2 13.67 -2.39%
S3 13.49 -3.62%

Accumulated Volume Support & Resistance Levels

Level Price
R3 16.01 14.32%
R2 15.70 12.14%
R1 14.40 2.86%
Price 14.00
S1 13.48 -3.71%
S2 13.11 -6.36%
S3 12.90 -7.86%

NVAX Predictions History

5 years ago
Jacob.Eloian.102802 predicted that NVAX for 2019-03-04 is going $0.700 (-0.36%)

Rank:

5 years ago
JS predicted that NVAX for 2019-03-01 is going $0.557 (-20.71%)

5 years ago
PumpTheseNumbers predicted that NVAX for 2019-03-01 is going $0.96 (37.08%)

5 years ago
Gp predicted that NVAX for 2019-03-01 is going $1.01 (43.77%)

5 years ago
Jason.Innerfield.102587 predicted that NVAX for 2019-03-01 is going $0.740 (4.95%)

Rank:

5 years ago
Bruce.Parrish.102216 predicted that NVAX for 2019-03-01 is going $1.68 (138.26%)

Rank:

5 years ago
PumpTheseNumbers predicted that NVAX for 2019-02-26 is going $2.05 (0.49%)

5 years ago
JS predicted that NVAX for 2019-02-26 is going $1.91 (-6.37%)

5 years ago
JS predicted that NVAX for 2019-02-26 is going $1.91 (-6.37%)

5 years ago
Gp predicted that NVAX for 2019-02-26 is going $2.02 (-0.98%)

Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT